Medical Devices
The ChallengeAs a result of ISO 14971:2007 edition, management at every level are required to have visibility into the top risks that are affecting their time-to-market, compliance to regulation and cost of quality today. Given the fact that risk analysis documents are not centrally managed or standardized, reporting of risk is very difficult and time consuming. Not only does manually preparing reports require time and effort, but also the data is inherently out-of-date and subject to human error.Another top business challenge is the need for a lifecycle approach to manage requirements and risks for traceability and compliance to FDA regulations. Currently, companies are managing these documents in disparate systems making later impact analysis due to change in requirements or risk documents a manual and error-prone process. Determining whether product failures experienced in the market were considered in the original product design is also a key challenge in the industry. Closing the loop to ensure post-market feedback is incorporated into the design and manufacturing process provides a higher quality product and improves FDA compliance. The Dyadem SolutionDyadem provides comprehensive Quality Risk Management (QRM) solutions that enable global Medical Device companies to reduce risk management effort by 50%-80%. In addition to improved quality and reduction in compliance risks, Dyadem also offers an integrated lifecycle model linking all parts of design and production risk analysis. This provides full traceability for FDA compliance and the identification of critical quality attributes to align design with manufacturing.Dyadem provides the essential elements of the ISO 14971 Risk Management System:
PHA-Pro FMEA-Pro FTA-Pro |
"In our industry, quality and risk management parameters are integrated into all aspects of research, development, production and application, as our products must perform flawlessly. Dyadem's software allows us to work in a more uniform environment, and assess quality in a standard way."
Genzyme Corporation
|


